The phase 2 ARACOG trial noted a greater decline in objectively measured cognitive function over 24 weeks among patients who received enzalutamide vs darolutamide for advanced prostate cancer.
"There is some evidence here, supported by our statistical analysis plan, that the classifier predicted the postulated benefits of adding docetaxel to ADT and enzalutamide," said Christopher Sweeney, MBBS, DHS.
Rana R. McKay, MD, FASCO, highlights phase 2 data on radium-223 dichloride plus cabozantinib for patients with renal cell carcinoma with bone metastases.
At a median follow-up of 42.8 months, median OS was 33.6 months (95% CI, 26.6–39.8) with EV+P (240 events/442 patients) vs 15.9 months (95% CI, 13.6–18.3) with chemotherapy (329 events/444 patients).
"Twenty-seven of 40 patients achieved a pCR amounting to a rate of 68%. Therefore, the null hypothesis could be rejected," said Richard Cathomas, MD.
Mark Fleming, MD, and Manoj Bupathi, MD, MS, highlight the key studies and sessions in GU oncology that they're most anticipating at ASCO 2026.
Christof Vulsteke, MD, PhD, shares in-depth insights on the 3.5-year analysis of the EV-302 trial, evaluating enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma.
Data also showed that ctDNA positivity at baseline was associated with worse DFS outcomes.
Although the primary end point was not met, Rana R. McKay, MD, highlighted a notable divergence in OS curves after 1 year that she described as a signal warranting further investigation.
Objective performance indicators in robotic surgery are providing the first quantitative framework for evaluating surgical technique, according to Michael Stifelman, MD, professor and chair of urology at Hackensack Meridian Health, whose early prostatectomy data link specific intraoperative metrics to functional outcomes—while governance frameworks, cultural adoption, and the prospect of real-time intraoperative guidance define the near-term challenges and long-term trajectory.
Break Wave lithotripsy met all pivotal non-inferiority end points vs shock wave lithotripsy.
"Don’t forget that the cost of living will go up over time, and keep in mind that your retirement expenses may change from year to year," writes Ronald J. Paprocki, JD, CFP, CHBC.
The approval is supported by data from the phase 3 POTOMAC trial.
Bilal I. Chughtai, MD, highlights 12-month cystoscopic data from the pivotal IDE trial of the Zenflow Spring System.
Daniel Eun, MD, highlights the challenges and recent progress in complex urologic reconstruction.
Keith Xavier, MD, URPS, highlights data from the TITAN 2 study looking at the impact of site of service on outcomes with the Medtronic implantable tibial neuromodulation system.
In this episode of Pearls & Perspectives, Amy Pearlman, MD, is joined by Larry I. Lipshultz, MD, to discuss the growing interest in peptides, including their potential applications in men’s health, evolving regulatory landscape, and what urologists need to know as patient demand continues to rise.
Archan Khandekar, MD, highlights key findings from a study evaluating LLM architectures for answering patient-facing urologic questions.
The AACU reflects on the diverse array of operational models across urology practices.
In this episode of The UroOnc Minute, host Adam B. Weiner, MD, speaks with Hashim U. Ahmed, BM BCh (Oxon), about patient selection, imaging, and the future direction of focal therapy for localized prostate cancer.
The application is supported by data from the phase 3 KEYNOTE-905/EV-303 trial.
Mark D. Tyson II, MD, MPH, discusses findings from the phse 3b PATAPSCO study, evaluating durvalumab plus BCG for patients with BCG-naïve, high-risk NMIBC.
Interim results from the pivotal Expander-2 showed sustained symptom improvement through 24 months with the Urocross Expander system for BPH.
Mark Garzotto, MD, discusses phase 3 data on aglatimagene besadenovec plus standard-of-care external beam radiation therapy with or without short-course androgen deprivation therapy in localized prostate cancer.
Bashir Al Hussein Al Awamlh, MD, MPH, discusses findings from an international registry study evaluating how baseline sexual interest may influence sexual bother outcomes after treatment for localized prostate cancer.
Sarah P. Psutka, MD, MSc, reflects on her AUA 2026 talk regarding frailty and surgical outcomes in urologic oncology.
Vesta Bladder Risk Stratify Dx applies AI foundation models to H&E pathology slides obtained during routine clinical care to generate prognostic risk assessments.
The agency issued a PDUFA target action date of January 6, 2027.
Rana R. McKay, MD, FASCO, shares results from the ARASEC study, which evaluated darolutamide plus ADT in mHSPC using a novel external control-arm design.
